2021
DOI: 10.1016/j.plabm.2021.e00212
|View full text |Cite
|
Sign up to set email alerts
|

The real life performance of 7 automated anti-SARS-CoV-2 IgG and IgM/IgA immunoassays

Abstract: Objectives This study was aimed at providing some insights into the real-life performance of the commercial, clinically validated anti-SARS-CoV-2 antibody assays. Methods The residual, anonymized samples from 97 patients referred for anti-SARS-CoV-2 antibodies testing were included in the study. The initial assessment was performed with the Euroimmun ELISAs, followed by the assays provided by: NovaTec, Snibe, Vircell, Roche, Abbott and DiaSorin. The analyses of the resu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 20 publications
0
8
0
Order By: Relevance
“…The multidimensional utility of anti-SARS-CoV-2 tests enforced rapid evolution in their characteristics. Simple lateral flow assays, generating qualitative results, were shortly superseded by laboratory-based automated methods [ 8 , 9 ]. Further improvements focused on antibody specificity [ 10 , 11 , 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…The multidimensional utility of anti-SARS-CoV-2 tests enforced rapid evolution in their characteristics. Simple lateral flow assays, generating qualitative results, were shortly superseded by laboratory-based automated methods [ 8 , 9 ]. Further improvements focused on antibody specificity [ 10 , 11 , 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…Before long, the attention switched to the automated immunochemical tests: enzyme-linked immunosorbent assays (ELISAs) and chemiluminescent immunoassays (CLIAs) [5]. These methods allowed for the semi-quantitative or quantitative measurement of IgA, IgM, and IgG antibodies solely against the nucleocapsid (N) antigen or against spike (S) antigen, and, in some tests, both antigens [6][7][8]. It was also recognized that the antigenic specificity of the antibodies is an important feature, influencing the clinical specificity and sensitivity of the assays [9][10][11][12][13].…”
Section: Introductionmentioning
confidence: 99%
“…This trajectory of antibody response may not necessarily apply for asymptomatic and mild cases of COVID-19 which do not develop nucleocapsid antibodies or for populations having SARS CoV-2 reinfection [39,44]. The S1-protein IgG Euroimmun ELISA reported higher rates of sample positivity compared with the S protein IgG Novalisa or the S-protein IgG automated immunoassays of Roche, Diasorin and Abbot [45]. In this respect, we are cautious about interpreting the S-protein IgG levels and acknowledge the higher sensitivity of Euroimmun ELISA for anti-S-protein IgG detection compared with the ELISA or the automated immunoassays of other manufacturers.…”
Section: Discussionmentioning
confidence: 99%